ArticleClinical case reports2026
Transitioning From Oral to Intravenous Treprostinil in Pulmonary Arterial Hypertension: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal approach to transitioning from oral treprostinil to intravenous treprostinil in pulmonary arterial hypertension (PAH) has been poorly characterized in published literature. We present a case involving a 21-year-old male with PAH experiencing worsening symptoms despite treatment with high doses of oral treprostinil (36.75 mg three times daily), ambrisentan, and tadalafil. The patient was admitted to our institution for transition from oral to intravenous treprostinil due to severe PAH as demonstrated on right heart catheterization (RHC). The transition process involved cross-tapering intravenous and oral treprostinil over 11 days with the aid of central venous pressure (CVP) measurements and noninvasive blood pressure monitoring. The patient remained clinically stable throughout the transition, and a repeat RHC upon completion demonstrated hemodynamic stability on a final dose of intravenous treprostinil 100 ng/kg/min. This case demonstrates that it is possible to safely transition from oral to intravenous treprostinil more rapidly than recommended by product labeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.